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Defective DNA repair by homologous recombination
(HR) is thought to be a major contributor to tumori-
genesis in individuals carrying Brca1 mutations.
Here, we show that DNA breaks in Brca1-deficient
cells are aberrantly joined into complex chromosome
rearrangements by a process dependent on the
nonhomologous end-joining (NHEJ) factors 53BP1
and DNA ligase 4. Loss of 53BP1 alleviates hypersen-
sitivity of Brca1 mutant cells to PARP inhibition and
restores error-free repair by HR. Mechanistically,
53BP1 deletion promotes ATM-dependent process-
ing of broken DNA ends to produce recombinogenic
single-stranded DNA competent for HR. In contrast,
Lig4 deficiency does not rescue the HR defect in
Brca1 mutant cells but prevents the joining of chro-
matid breaks into chromosome rearrangements.
Our results illustrate that HR and NHEJ compete to
process DNA breaks that arise during DNA replica-
tion and that shifting the balance between these
pathways can be exploited to selectively protect or
kill cells harboring Brca1 mutations.
INTRODUCTION
Mutations in the Brca1 gene predispose carriers to a high inci-
dence of breast and ovarian cancer (Venkitaraman, 2004).
In the absence of Brca1, Xrcc2, or other homologous recombina-
tion (HR) proteins, Rad51 foci formation and homology depen-
dent repair are impaired (Moynahan et al., 1999; Scully et al.,1999). Since the HR pathway is required for repair of sponta-
neous double-stranded breaks (DSBs) that arise during DNA
replication, defects in HR result in an accumulation of chromatid
breaks (Andreassen et al., 2006; Sonoda et al., 1998). Cells that
cannot repair chromatid breaks by HR become more reliant on
other poorly defined alternative repair pathways. These path-
ways are not template based like HR and therefore have the
propensity to join together DSBs on different chromatids to pro-
duce complex chromosomal rearrangements, which promote
genomic instability and/or trigger loss in viability (Bryant et al.,
2005; Farmer et al., 2005; Sonoda et al., 1998). Genomic insta-
bility following loss-of-function of Brca1 is hypothesized to be
a key factor leading to tumorigenesis in individuals with the
Brca1 mutation; nevertheless, additional mutations are required
to enable survival and outgrowth of tumor cells (Deng, 2006;
Venkitaraman, 2004).
HR-deficient cells exhibit an acute sensitivity to killing by
inhibitors of the single-stranded DNA (ssDNA) repair protein
poly(ADP-ribose) polymerase (PARP) (Bryant et al., 2005; Farmer
et al., 2005; Jackson and Bartek, 2009). Mechanistically, loss of
PARP activity prevents repair of ssDNA breaks, which are then
converted into DSBs during DNA replication. These breaks are
normally repaired by Rad51-dependent HR using the sister chro-
matid as a template, hence PARP inhibition is particularly toxic in
Brca1- or Brca2-deficient cells, which are HR defective. The
ability of PARP inhibitors to selectively kill HR-deficient cells is
currently being used in clinical trials for treatment of breast and
ovarian cancers where Brca1 or Brca2 is mutated (Fong et al.,
2009; Jackson and Bartek, 2009). More recently, it has been
observed that Brca2-deficient tumors are capable of acquiring
reversion mutations that enable resistance to chemotherapeutic
agents (Edwards et al., 2008; Sakai et al., 2008). This observation
raises the possibility that additional secondary mutations couldCell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc. 243
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Figure 1. Deletion of 53BP1 Reduces
Mammary Tumorigenesis, Radial Chromo-
some Formation, and Cellular Proliferation
Defects in Brca1D11/ D11 Cells
(A) Breast cancer incidence in mice deficient in
Brca1. The red line indicates tumor incidence in
mice with deletion of Brca1 exon 11 targeted to
the mammary cells with a Cre transgene under
control of the MMTV LTR promoter (Brca1f/f;
MMTV-Cre). The blue line shows mammary tumor
incidence in Brca1D11/ D1153BP1/mice, in which
Brca1 exon 11 and 53BP1 are deleted in all cells.
(B) Radial chromosome structures characteristic
of metaphases from Brca1D11/ D11p53+/ B cells.
The percentage of metaphases containing radial
chromosomes in Brca1D11/ D11p53+/ (n = 300),
Brca1D11/ D1153BP1/ (n = 300) and WT (n =
100) cells is indicated. Note that equivalent
results were seen with Brca1D11/ D11p53+/ and
Brca1D11/ D11p53/cells.
(C) Flow cytometry analysis of B cells to measure
cell survival. The labeled populations in the dot
plots are viable cells, identified by their ability to
exclude PI and their lack of caspase 3 activation.
The chart shows the frequency of live cells treated
with PARP inhibitor normalized to the untreated
population.
(D) Proliferation of B cells pulsed with CFSE and
cultured with and without PARP inhibitor. CFSE
signal diminishes with increasing cell division, so
that cells that do not divide have the highest
CFSE signal.
See also Figure S1.mediate resistance of Brca-deficient tumors to the toxic effects
of PARP inhibitors.
Mice homozygous for the exon 11 deletion (D11) isoform of
Brca1 (Brca1D11/D11) die in utero (Xu et al., 2001). Embryonic
cell death is associated with extensive apoptosis and activation
of the ATM-Chk2-p53 arm of the DNA damage response (Cao
et al., 2006). Indeed, embryonic lethality can be rescued by
complete or heterozygous loss of p53 (Xu et al., 2001) or deletion
of ATM or Chk2 (Cao et al., 2006). Deletion of 53BP1 also
rescues the viability ofBrca1D11/D11mice (Cao et al., 2009). How-
ever, in contrast to rescue by loss of p53, Brca1D11/D1153BP1/
mice exhibit a low incidence of tumor formation and near-normal
life span (Cao et al., 2009). Nevertheless, Brca1D11/D1153BP1/
cells showed elevated levels of DSBs, intact ATM-Chk2-p53
signaling, and ionizing radiation (IR)-induced apoptosis (Cao
et al., 2009).
The only known functions of 53BP1 are in transducing a subset
of ATM-dependent cell-cycle checkpoints (DiTullio et al., 2002;
Fernandez-Capetillo et al., 2002; Lee et al., 2010; Wang et al.,
2002) and facilitating the joining of distal DSBs formed at
dysfunctional telomeres and during lymphocyte antigen receptor
recombination (Difilippantonio et al., 2008; Dimitrova et al., 2008;
Manis et al., 2004; Reina-San-Martin et al., 2007; Ward et al.,
2004). None of these activities would appear to account for the
survival of Brca1D11/D11 mice in the absence of 53BP1. Thus,
the underlying mechanism by which loss of 53BP1 rescues cell
death and prevents tumorigenesis in Brca1mutant mice remains
unclear.244 Cell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc.Here, we show that the presence of 53BP1 limits the capacity
of Brca1-deficient cells to accurately repair DSBs. Importantly,
the high levels of genomic instability and cell death induced in
Brca1-deficient cells by treatment with an inhibitor of PARP are
not present in Brca1/53BP1 double-deficient cells. Genomic
stability is rescued because the HR pathway is largely restored
in cells lacking Brca1 and 53BP1. In contrast, Brca1-deficient
repair is not normalized by deletion of the nonhomologous
end-joining (NHEJ) factor DNA ligase 4 (Lig4), although deletion
of Lig4 does prevent accumulation of chromosomal fusions.
Our results indicate a role for 53BP1 and Brca1 in regulating
the choice between NHEJ and HR pathways, which has implica-
tions for anticancer therapies using PARP inhibitors.
RESULTS
53BP1 Promotes Genomic Instability and Mammary
Tumorigenesis in Brca1 Mutant Mice
Brca1D11/D11 mice rescued by loss of one or both copies of p53
(Brca1D11/D11p53+/or Brca1D11/D11p53/) develop multiple
types of tumors (Cao et al., 2006; Xu et al., 1999), whereas
rescue by deletion of 53BP1 (Brca1D11/D1153BP1/) results in
near normal life span with significantly reduced tumorigenesis.
To further investigate the requirement for 53BP1 in tumorigen-
esis in Brca1-deficient animals, we followed the onset of devel-
opment of mammary tumors in cohorts of female mice with dele-
tion mutations in Brca1 exon 11 (Figure 1A). As expected, mice
with breast-specific deletion of Brca1 exon 11 succumbed to
1 0 31 3 2
7
28
102
8 10
22
0
50
100
150
0 10 nM 1 μM
WT
53BP1-/-
Brca1Δ11/Δ11
p53-/-
Brca1Δ11/Δ11
53BP1-/-
0 0 01 0 04
68
76
4 0
16
0
20
40
60
80
0 10 nM 1 μM
WT
53BP1-/-
Brca1Δ11/Δ11
p53-/-
Brca1Δ11/Δ11
53BP1-/-
0 0 00 0 1
11
94
320
1 6 8
0
100
200
300
400
0 10 nM 1 μM
WT
53BP1-/-
Brca1Δ11/Δ11
p53-/-
Brca1Δ11/Δ11
53BP1-/-
Kap1-S824 Kap1-S824
Tubulin Tubulin
PARPi -      + -      + -      + IR -      + -     + -     +
semosomorhclaidaR
sesahpatem001rep
skaerb
e
moso
morhC
sesahpate
m
001rep
A
Brca1Δ11/Δ11
p53-/-
Brca1Δ11/Δ11
53BP1-/-
WT Brca1Δ11/Δ11
p53-/-
Brca1Δ11/Δ11
53BP1-/-
WT
skaerbditamorhC
sesahpatem001rep
[PARPi]
B
[PARPi]
[PARPi]
C
snoitarrebA
sesahpatem001rep
0
8
0
54
18
14
0
6
0
0
10
20
30
40
50
60
Radial
chromosomes
Chromosome
breaks
Chroma d breaks
WT
Brca1Δ11/Δ11
p53-/-
Brca1Δ11/Δ11
53BP1-/-
+ CPT
Figure 2. Deletion of 53BP1Reverses Sensi-
tivity of Brca1D11/ D11 Cells to PARPi and
Camptothecin
(A) Analysis of genomic instability in metaphases
from B cells treated with 0, 10 nM, and 1 mM
PARP inhibitor. Charts show the number of radial
chromosomes, chromatid breaks, and chromo-
some breaks per 100 metaphases (n = 50 meta-
phases analyzed in each case). Note that genomic
instability in Brca1D11/ D11 cells is independent of
p53 status, and equivalent results were seen in
Brca1D11/ D11p53+/ and Brca1D11/ D11p53/
cells.
(B) Western blot showing Kap1 phosphorylation in
B cells from the indicated genotypes treated with
PARP inhibitor or 5Gy ionizing radiation.
(C) Analysis of genomic instability in metaphases
from B cells treated with 4 nM camptothecin
(CPT). B cells were cultured overnight with CPT
prior to fixation and preparation of metaphase
slides.tumors of the mammary tissue (Brodie et al., 2001; Xu et al.,
1999), with 12 out of 27 animals affected by 18 months of age
(Figure 1A). Mice that were doubly deficient for Brca1 exon 11
and 53BP1, by contrast, developed almost no breast tumors,
with just one animal affected at the age of 22 months (Fig-
ure 1A; data not shown).
Brca1 is thought to suppress malignancy by promoting HR
(Moynahan et al., 1999; Scully et al., 1999; Venkitaraman,
2004). In light of the dramatic reduction in the frequency of
mammary tumors in Brca1D11/D1153BP1/ animals, we hypoth-
esized that loss of 53BP1 might specifically affect the ability
of Brca1-deficient cells to repair replication-associated DNA
damage. To test this, we examined chromosomal aberrations in
metaphase spreads from WT, Brca1D11/D11p53+/ and
Brca1D11/D1153BP1/ B cells that were stimulated to divide ex
vivo for 3 days. Asymmetric radial chromosome structures, a
type of chromatid exchange characteristic of HR deficiency,
were found in 10.7%of Brca1D11/D11p53+/Bcells (n = 300) (Ven-
kitaraman, 2004) (Figure 1B). Strikingly, these chromosomeaber-
rations were present in just 1.0% of Brca1D11/D1153BP1/ cells,Cell 141, 243–2equivalent to a 10-fold reduction relative
to Brca1D11/D11p53+/ (n = 300). Radial
chromosomes were undetectable in WT
and53BP1/ cells (n =100 cells analyzed
for each genotype; Figures 1B and 2A).
To exclude the possibility that p53
heterozygosity provides a survival advan-
tage to genomically unstable Brca1-defi-
cient cells by allowing aberrant chromo-
somes to persist (Calle´n et al., 2007;
Difilippantonio et al., 2008), we quantified
the incidence of radial chromosomes in
Brca1D11/D11conditional B cells. By infect-
ing these cells with a virus expressing Cre
recombinase, we were able to specifically
delete Brca1 exon 11 in p53-sufficientcells. We found that theseBrca1f/f cells still showed a significant
increase (8-fold) in the number of radial chromosomes relative
to Cre-infected Brca1f/f 53BP1/cells (Figure S1A available
online). Radial chromosome formation in Brca1f/f cells is there-
fore independent of p53 status but dependent on 53BP1.
To investigate further the effect of 53BP1 in regulating repair
of DNA breaks occurring during replication, we challenged
Brca1 mutant cells with a chemical inhibitor of PARP (PARPi;
KU58948) (Figures 1C and 1D). This drug has been shown to
cause cell death in Brca1-deficient cells, associated with high
levels of genomic instability (Farmer et al., 2005). In the presence
of PARPi, Brca1D11/D11p53+/ cells showed much lower levels of
survival relative to either WT or Brca1D11/D1153BP1/ cells (Fig-
ure 1C). Equivalent PARPi-induced cell death was seen with
Brca1D11/D11p53/ cells, which were nonetheless resistant to
IR-induced apoptosis (Figure S1B). Thus, PARPi-mediated
apoptosis in Brca1D11/D11 cells, in contrast to IR-induced apo-
ptosis, occurs independently of p53 status.
The ability of PARPi to inhibit cell proliferation in culture
was measured by pulsing of the cells with the fluorescent dye54, April 16, 2010 ª2010 Elsevier Inc. 245
CFSE (carboxyfluorescein succinimidyl ester). In this assay,
cellular proliferation is revealed by stepwise loss of CFSE during
the culture period. PARPi inhibited growth in Brca1D11/D11p53+/
cells (Figure 1D), as well as in Brca1D11/D11p53/ B cells (see
below). Brca1D11/D1153BP1/ cells were distinct in that they
were practically insensitive to PARPi-induced apoptosis and
divided almost normally whether or not PARPi was present
(Figures 1C and 1D). Consistent with these findings in B cells,
Brca1D11/D1153BP1/ mouse embryonic fibroblasts (MEFs)
were also insensitive to cell killing with PARPi, whereas
Brca1D11/D11 MEFs were hypersensitive to the drug (Fig-
ure S1C). We conclude that 53BP1 is required for the toxic effect
of PARP inhibition on Brca1D11/D11 cells.
PARPi is predicted to increase the frequency of S phase-asso-
ciated chromosomal aberrations (Bryant et al., 2005; Farmer
et al., 2005; Jackson and Bartek, 2009). To determine whether
loss of 53BP1 affects S phase-specific genomic instability, we
monitored the level of chromosome breaks and radial structures
inBrca1-deficient cells treated with andwithout PARPi. Whereas
WT and 53BP1/ cells showed very low levels of genomic
instability in the presence or absence of PARPi, exposure of
Brca1D11/D11p53/ to PARPi caused a substantial increase in
the level of genomic instability (Figure 2A). For example, treat-
ment of Brca1D11/D11p53/ cells with 1 mM PARPi increased
the frequency of radial chromosomes from 0.1 per cell to an
average of 3.2 per cell and increased the number of DSBs (chro-
matid and chromosome) from 0.1 to 1.8 per cell. Thus, PARPi
treatment of Brca1D11/D11p53/ cells leads to a greater than
20-fold increase in aberrations (Figure 2A). In contrast, the total
frequency of chromosomal aberrations in PARPi-treated
Brca1D11/D1153BP1/ cells was just 0.5 per cell, which is 10-fold
lower than PARPi-treated Brca1D11/D11p53/ cells. Neverthe-
less, PARPi-induced genomic instability inBrca1/53BP1 double-
mutant mice was somewhat elevated relative to the WT.
Our findings were further substantiated by the observation
that PARPi induced a significant amount of DNA damage
signaling in Brca1D11/D11p53/ cells. Brca1D11/D11p53/ cells
preincubated with PARPi for 24 hr showed induction of Kap1
phosphorylation (Figure 2B), while phosphorylated Kap-1 was
undetectable in PARPi-treated WT and Brca1D11/D1153BP1/
cells (Figure 2B). This was not due to an intrinsic defect in
ATM signaling, because similar levels of Kap1 phosphorylation
were detected in cells from all genotypes treated with IR
(Figure 2B).
To determine the effects of other chemotherapeutic agents
that induce replication damage, we challenged WT, Brca1-,
and Brca1/53BP1-deficient B cells with camptothecin (CPT).
CPT and its derivatives are topoisomerase I poisons that induce
DSBs during replication and are widely used as anticancer drugs
(Jackson and Bartek, 2009). Brca1-deficient cells are hypersen-
sitive to CPT (Nakamura et al., 2010). Consistent with this,
after treatment of Brca1D11/D11p53+/ B cells with 4 nM CPT,
radial chromosomes formed at a frequency of 0.54 per cell,
whereas these aberrations were undetectable in CPT-treated
Brca1D11/D1153BP1/ B cells (Figure 2C). Similarly, loss of
53BP1 suppressed CPT-induced chromosome and chromatid
breaks in Brca1-deficient cells (Figure 2C). Thus, loss of 53BP1
greatly alleviates replication-associated aberrations and toxicity246 Cell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc.that clinically relevant chemotherapeutic agents confer on
Brca1-deficient cells.
Loss of 53BP1 Increases HR in Brca1 Mutant Cells
Replication-associated breaks are primarily repaired by HR. We
therefore hypothesized that loss of 53BP1 might restore HR,
a DNA repair pathway that is significantly compromised in the
absence of Brca1 (Moynahan et al., 1999). To test this, we first
examined Rad51 foci formation, a marker of HR, which is
impaired in Brca1 mutant cells (Bhattacharyya et al., 2000;
Scully et al., 1997). WT, Brca1D11/D11p53+/, and Brca1D11/D11
53BP1/ B cells were treated with IR, fixed, and stained with
a Rad51 antibody (Figure 3A). Whereas Rad51 foci formed in
just 6.8% of irradiated Brca1D11/D11p53+/ cells, more than
30%of Brca1D11/D1153BP1/ cells exhibited Rad51 foci, similar
to that observed in WT cells (Figure 3A). Differences in the fre-
quency of Rad51 foci formation was not due to alterations in
cell-cycle distribution, as the percentage of cycling cells was
equivalent in all genotypes tested (Figure S2).
As a second measure of HR, we monitored sister chromatid
exchanges (SCEs), which are dependent on Rad51 activity
(Sonoda et al., 1999). While the basal level of SCEs was the
same, treatment with PARPi increased the frequency of SCEs
in Brca1D11/D1153BP1/ but not in Brca1D11/D11p53+/ cells
(Figure 3B). PARPi treatment of Brca1D11/D11p53+/ therefore
leads to an increase in aberrant radial chromosome formation,
which is a marker of HR deficiency (Figure 2A), whereas PARPi
treatment of Brca1D11/D1153BP1/ cells promotes sister chro-
matid exchange, which is a marker of HR proficiency (Figure 3B).
As a third measure of HR, we used the DR-GFPhyg reporter
system, which is designed to measure error-free HR of a site-
specific break formed by the rare-cutting endonuclease I-SceI
(Nakanishi et al., 2005) In this reporter, error-free HR repair of
the I-SceI-induced DSB leads to restoration of a GFP+ gene
that uses iGFP as the template (Figure 3C). To analyze repair
of chromosomal breaks, we integrated DR-GFPhyg into WT,
Brca1D11/D11, and Brca1D11/D11 53BP1/ immortalized MEF cell
lines. From these experiments, we found that HR in Brca1D11/D11
cells was reduced relative to theWT (3-fold, p < 0.0001), whereas
HR in Brca1D11/D11 53BP1/ cells was increased relative to the
WT (5-fold, p < 0.0028) (Figure 3C). Thus, in Brca1D11/D11 MEFs,
loss of 53BP1 causes a 16-fold increase in HR repair of a site-
specific chromosomal break. In conclusion, loss of 53BP1
increases HR in Brca1 mutant cells, as evidenced by Rad51
foci, sister chromatid exchange, and recombination reporter
assays.
53BP1 Does Not Affect the Activity of Xrcc2 in HR
To examine whether loss of 53BP1 could rescue the defects in
cells deficient in other HR components, we examined chromo-
somal aberrations in cells from mice deficient for Xrcc2, a
Rad51 paralog that, like Brca1, is required for Rad51 foci forma-
tion (Liuet al., 1998; Takataet al., 2001).Metaphasespreadswere
prepared from conditional Xrcc2f/f B cells, in which Xrcc2 was
deleted with a B cell-specificCD19-Cre transgene. As expected,
Xrcc2-deficient cells stimulated to proliferate in vitro exhibited
chromosome and chromatid breaks and radial chromosomes,
which was increased by treatment with PARPi (Figure 3D).
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Figure 3. Deletion of 53BP1 Restores HR in
Brca1 but Not Xrcc2 Mutant Cells
(A) Immunofluorescence images showing Rad51
foci (red) with DAPI counterstain (blue) in cells of
the indicated genotypes after treatment with
ionizing radiation. Chart shows the percentage of
cells with Rad51 foci (n = 100 counted for each
genotype).
(B) B cells grown for 36 hr in BrdUTP were fixed
and metaphases prepared to visualize individual
sister chromatids. Sister chromatid exchanges
(SCEs) in metaphase chromosomes are indicated
with arrows in the image in the top panel. The chart
shows themean SCEs in metaphase spreads from
B cells of the indicated genotypes treated with and
without PARP inhibitor. Error bars show the SD.
(C) Top: Structure of the HR reporter substrate
DR-GFPhyg is shown, along with the HR product
expressing a functional GFP+ gene. Bottom:
Frequency of HR relative to total transfected cells
in WT, Brca1D11/D11, and Brca1D11/D1153BP1/
MEFs, as measured with the DR-GFPhyg reporter.
*p < 0.0001 between WT and Brca1D11/D11, *p <
0.0028 between WT and Brca1D11/D11 53BP1/.
(D) Analysis of genomic instability in metaphases
from B cells treated with and without PARP inhib-
itor (1 mM). B cells were homozygous for a
conditional Xrcc2 allele that was deleted with
a B cell-specific CD19-Cre transgene to produce
knockout Xrcc2f/f, and Xrcc2f/f53BP1/ cells.
Charts show the number of radial chromosomes,
chromatid breaks and chromosome breaks per
100 metaphases (n = 50 metaphases analyzed in
each case).
See also Figure S2.Surprisingly, whereas 53BP1deletion promoted genome stability
in Brca1-deficient cells (Figure 2A and Figure S1), this effect was
not seen in Xrcc2 knockout cells (Figure 3D). Rather, the
frequency of breaks and asymmetric radial chromosomes was
similar in Xrcc2f/f53BP1/ and Xrcc2f/f cells. Thus, despite
the fact that both Brca1 and Xrcc2 are required for Rad51 foci
formation during HR, loss of 53BP1 reverses the HR defect in
Brca1- but not in Xrcc2-deficient cells. We hypothesize that
Brca1 affects an early stage of HR (Stark et al., 2004), whereas
Xrcc2 acts at a downstream step that is not affected by the pres-
ence of 53BP1 (Nagaraju et al., 2009) (see theDiscussion, below).
Lig4 Is Required for Radial Fusions inBrca1Mutant Cells
As measured by reporter substrates, the frequency of HR is
enhanced in the absence of the NHEJ proteins Ku70, XRCC4,Cell 141, 243–2and DNA-PKcs (Pierce et al., 2001), as
well as by overexpression of a dominant
negative 53BP1 fragment (Xie et al.,
2007), suggesting that proteins of the
NHEJ pathway can have suppressive
effects on HR. Lig4 plays an essential
role in NHEJ, so we hypothesized that
Lig4 deficiency might also rescue the
HR defect in Brca1 mutant cells. To testthis hypothesis, we used Cre-mediated deletion to delete con-
ditional alleles of Lig4 and Brca1 to make B cells homozygous
for the knockout Lig4f/f andBrca1f/f alleles. We scored the level
of chromosomal aberrations in mitotic spreads from these cells
after overnight treatment with 1 mM PARPi. Whereas WT and
Lig4f/f cells treated with PARPi did not accumulate DNA
damage, 80% of Cre-infected Brca1f/f cells exhibited chromo-
somal instability (Figure 4A). Aberrant Brca1f/f cells contained
0.8 chromatid breaks/cell, and most contained two or more
radial fusions per cell, indicating that the majority of breaks are
resolved into complex chromosome rearrangements in Brca1
mutant cells (Figure 4A). Sixty percent of PARPi-treated
Brca1f/f Lig4f/f displayed genomic instability. However, only
0.66 radials/cell were present in Brca1f/f Lig4f/f cells, as
opposed to Brca1f/f, where approximately 2.1 radials/cell54, April 16, 2010 ª2010 Elsevier Inc. 247
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Figure 4. Deletion of Lig4 Inhibits Formation
of Radial Chromosomes but Does Not
Rescue Cell Proliferation or Genomic insta-
bility in Brca1D11/ D11 Cells
(A) Analysis of genomic instability in metaphases
from B cells treated with PARP inhibitor (1 mM).
Conditional Brca1 and Lig4 alleles were deleted
using pMX-Cre-GFP retroviral transduction to
generate B cells that were homozygous for the
knockout Brca1f/f and Lig4f/f alleles. The left chart
shows the percentage of metaphases with
genomic instability from cells of the indicated geno-
types. The right chart quantifies the distribution of
radial chromosomes, chromatid breaks (ctd) and
chromosome breaks (csb) among the aberrant
metaphases (n = 50 metaphases of each genotype
analyzed).
(B) Cell survival after treatment with PARP inhibitor.
Cultured B cells homozygous for conditional Brca1
and Lig4 alleles were infected with pMX-Cre-GFP
retrovirus to produce GFP+ knockout Brca1f/f
and Lig4f/f cells. The chart shows the percentage
of GFP+ cells that were present in B cell cultures
of the indicated genotypes five days post-infection.
PARP inhibitor treatment (10 nM or 1 mM) led to
disappearance of Brca1f/f and Brca1f/f Lig4f/f
cells from the cultures.
(C) Chart showing the percentage of cells with
Rad51 foci after ionizing radiation as measured by
immunofluorescence (nR 160 cells).
(D) Frequency of radial chromosomes in meta-
phase spreads from Brca1D11/ D11p53+/ B cells
cultured for 24 hr with either PARP inhibi-
tor (PARPi) or PARPi + DNA-PKcs inhibitor
(DNAPKi).were observed. Instead, Brca1f/f Lig4f/f cells were character-
ized by high levels of unresolved chromatid breaks (average of
2.5 per cell versus 0.8 in Brca1f/f cells; Figure 4A). Thus, unlike
53BP1 deficiency, which reduces all types of chromosome
aberrations in Brca1-deficient cells (Figure 2A), Lig4 deletion
only affects the frequency of radial chromosomes. Lig4 therefore
appears to be specifically required for the processing of chro-
matid breaks into radial fusions in Brca1 mutant cells.
To test whether the accumulation of chromatid breaks in
Brca1f/f Lig4f/f cells has an effect on cell growth and survival,
we compared the viability of WT, Lig4f/f, Brca1f/f, and Brca1f/
fLig4f/f B cells that were treated with or without PARPi for 5
days. While Cre-infected WT and Lig4f/f cells were insensitive
to PARPi (Figure 4B), there was a precipitous
drop in live Cre-infected (GFP+) Brca1f/f and Brca1f/fLig4f/f248 Cell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc.cells in response to PARPi (Figure 4B).
Thus, Lig4 deficiency does not relieve the
toxic effects of PARPi on Brca1-deficient
cells.
To determine whether loss of Lig4, like
53BP1 deficiency, rescues the HR defect
in Brca1 mutant cells, we examined IR
induced Rad51 foci formation. Whereas
more than 25% of WT and Brca1f/f53BP1/ Cre-infected cells exhibited Rad51 foci, Rad51 foci
formed at a lower frequency (8%–11%) in Brca1f/f and
Brca1f/f Lig4f/f cells (Figure 4C). Thus, despite the fact that
both Lig4 or 53BP1 deficiency abrogates PARPi-induced radial
fusions in Brca1mutant cells, only 53BP1 but not Lig4 deficiency
rescues PARPi induced cell death, chromosomal instability, and
defects in IR-induced Rad51 foci formation. Similarly, we found
that inhibition of the kinase activity of DNA-dependent protein
kinase (DNA-PKcs), which is considered a key component of
the NHEJ repair pathway, did not reduce radial chromosome
formation in PARPi-treated Brca1-deficient cells (Figure 4D).
Reversal of genomic instability in Brca1D11/D11cells is therefore
dependent on loss of 53BP1 and cannot be achieved by inacti-
vation of any component of the nonhomologous end-joining
pathway.
0.0
0.8
0.0
12.1
0
5
10
15
20
0
10
20
30
40
50
untreated + ATMi
A B
Ra
dia
l c
hro
mo
so
me
s 
pe
r 1
00
 m
eta
ph
as
es
untreated ATMi PARPi ATMi 
+PARPi 
53
BP
1-
/-
W
T
Tubulin
RPA-pS4/8
Kap1-pS824
Brc a1 φ/φ
L ig4 φ/φ
Brc a1φ/φ Brc a1 φ/φ
53BP1-/ -
W T
Kap1-pS824
RPA-pS4/8
Tubulin
DC
Kap1-pS824
RPA-pS4/8
Tubulin
53
BP
1-
/-
W
T
-  - + +30 Gy IR
RPA-pS4/8
Tubulin
EBrca1Δ11/Δ11
53BP1-/-
CFSE CFSE
ATMi - - +
30 Gy IR  - +  +
Brca1Δ11/Δ11
53BP1-/-
Kap1-pS824
CTIP
shRNA - - CTIP CTIP
30 Gy IR - + - +
F
Brca1Δ11/Δ11
53BP1-/-
G
Brca1Δ11/Δ11
53BP1-/-
% 
Ce
lls 
wit
h R
ad
51
 fo
ciBrca1Δ11/Δ11
p53-/-
Brca1Δ11/Δ11
53BP1-/-
-       -           +          +30 Gy IR
Figure 5. Rescue of Homologous Recombi-
nation in Brca1D11/ D11 Cells by 53BP1 Dele-
tionCorrelateswith Increased Phosphoryla-
tion of RPA and Is Dependent on ATM and
CtIP
(A) Western blot analysis showing Kap1 and RPA
phosphorylation in WT and 53BP1/ cells in
response to 30Gy ionizing radiation.
(B) RPA and Kap1 phosphorylation after 30Gy
ionizing radiation in Brca1- and Lig4-deficient
cells. Knockout Brca1f/f and Lig4f/f cells were
prepared by sorting of B cells homozygous for
the conditional alleles after infection with pMX-
Cre-GFP retrovirus.
(C) Western blot showing Kap1 and RPA phos-
phorylation in Brca1D11/ D1153BP1/ cells after
30Gy ionizing radiation with and without ATM
inhibitor (KU55993). ATMi (5 mM) was added 2 hr
prior to irradiation.
(D) Western blot analysis showing ionizing radia-
tion-induced RPA phosphorylation inBrca1D11/ D11
53BP1/ MEFs after CtIP shRNA. Protein lysates
were prepared from cells infected with either
vector () or CtIP shRNA (CTIP), with and without
30 Gy ionizing radiation.
(E) Quantification of radial chromosome structures
in metaphases from Brca1D11/ D1153BP1/ cells
treated with ATM inhibitor (5 mM) and/or PARP
inhibitor (1 mM). ATMi was added at the start of
the B cell culture, PARPi at 24 hr, and metaphases
were made at 48 hr (nR 240 metaphases; mean ±
SD is shown from two experiments).
(F) CFSE dilution analysis showing proliferation of
B cells cultured with ATM inhibitor and/or PARP
inhibitor for 96 hr.
(G) Quantification of Rad51 foci in Brca1D11/ D11
53BP1/Bcells. Rad51 foci were inducedwith 5Gy
of ionizing radiation and cells fixed for Rad51 stain-
ing 2 hr later. Cells were either untreated or pre-
treated for 2 hr with 5 mM ATM inhibitor.
See also Figure S3.Loss of 53BP1 Promotes RPA Phosphorylation
in a Manner Dependent on ATM and CtIP
Brca1 has been implicated in 50-30 DSB resection (Schlegel et al.,
2006; Yun and Hiom, 2009a), which involves the nucleolytic pro-
cessing of DSBs to produce ssDNA overhangs that are required
for HR (Mimitou and Symington, 2009). During the process of
resection, replication protein A (RPA) is loaded onto ssDNA,
where it is then phosphorylated. To determine whether loss of
53BP1 affects resection, we irradiated WT and 53BP1/ B cells
and assessed phosphorylation of RPA and Kap-1. Kap-1 phos-
phorylation, which occurs independently of DSB resection,
was similar in irradiated WT and 53BP1/ cells (Figure 5A);
however, the level of RPA phosphorylation was consistently
higher in 53BP1/ cells (Figure 5A). We conclude that 53BP1
suppresses RPA phosphorylation.
To test whether 53BP1 or Lig4 inhibits RPA phosphorylation in
Brca1 mutant cells, we compared the levels of phosphorylation
in WT, Brca1f/f, Brca1f/f53BP1/, and Brca1f/f Lig4f/f cells.
Whereas Brca1f/f and Brca1f/f Lig4f/f B cells had similarly
decreased levels of phosphorylated RPA compared to the WT
(Figure 5B), importantly, Brca1f/f53BP1/ B cells displayeda rescue of RPA phosphorylation to near WT levels (Figure 5B).
Thus, loss of 53BP1 but not Lig4 is able to promote ssDNA
formation competent for RPA phosphorylation. This may explain
why combined deficiencies in Brca1/53BP1 but not Brca1/Lig4
reverse the HR defect in Brca1 mutant cells.
To provide physical evidence for resection of DSBs in
53BP1/ cells, we measured the degree of DNA processing at
chromosomal translocation junctions. B cells containing I-SceI
sites integrated into the c-myc (MycI allele) and IgH locus (IgHI
allele) were infected with a retrovirus encoding I-SceI to induce
translocations between c-myc and IgH (Figure S3A). In this
system, translocation breakpoints are found at various dis-
tances from the site of I-SceI induced DSBs, dependent on the
degree of nucleolytic processing at the break site (Robbiani
et al., 2008). We used PCR to map translocation breakpoints
induced by the I-SceI system in AID/ and AID/53BP1/
cells (Figure S3B; use of AID/ cells restricts translocations to
breaks induced by I-SceI). All of the sequenced junctions
showed processed DNA ends (Figure S3C). However, the
average total distance of the breakpoint position from the
I-SceI sites on c-myc and IgH was approximately 2-fold greaterCell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc. 249
in AID/53BP1/ cells compared with AID/ (average resec-
tion, AID/: 448.2 nucleotides, versus AID/53BP1/: 742.3
nucleotides, p = 0.032) (Figure S3C). Thus, loss of 53BP1
enhances nucleolytic processing of DNA ends. These findings
are consistent with enhanced degradation of coding ends during
V(D)J recombination in 53BP1/ mice (Difilippantonio et al.,
2008), and inhibition of DNA end resection by the yeast 53BP1
homolog, Rad9 (Lazzaro et al., 2008).
Rescue of Brca1 Mutant Cells by 53BP1 Deletion
Is Dependent on ATM
ATM kinase activity is required for nucleolytic processing of
DSBs to generate RPA-coated ssDNA (Jazayeri et al., 2006).
The CtIP protein is phosphorylated by ATM after DNA damage
induced by IR (Li et al., 2000) and forms a complex with
Mre11/Rad50/Nbs1 and Brca1, which is required for DSB resec-
tion (Chen et al., 2008; Sartori et al., 2007; Yun andHiom, 2009a).
Prompted by these findings, we tested whether ATM activity and
CtIP mediates the resection observed in Brca1D11/D1153BP1/
cells. We found that Brca1D11/D1153BP1/ B cells pretreated
with ATM inhibitor (ATMi, KU55993) (Hickson et al., 2004)
showed a significantly lower level of phosphorylated RPA after
irradiation (Figure 5C). Similarly, Brca1D11/D1153BP1/ MEFs
infected with CtIP short hairpin RNA (shRNA) showed impair-
ment of RPA phosphorylation (Figure 5D). Thus, the increase in
DSB resection promoted by the absence of 53BP1 is ATM and
CtIP dependent.
Since increased RPA phosphorylation in Brca1/53BP1
double-deficient cells correlates with rescued genomic sta-
bility, we tested whether inhibition of the ATM-dependent
pathway leading to RPA phosphorylation would sensitize
Brca1D11/D1153BP1/ cells to the effects of PARPi. Treatment
of Brca1D11/D1153BP1/ cells with ATMi induced a small
increase in the frequency of radial chromosomes, and combina-
tion of ATMi and PARPi led to a 15-fold enhancement in radials
relative to ATMi alone (Figure 5E). Moreover, ATMi re-sensitized
Brca1D11/D1153BP1/ cells to PARPi, evidenced by its ability to
inhibit the growth of B cells (Figure 5F). Finally, ATMi reduced
Rad51 foci formation in Brca1D11/D1153BP1/ cells (Figure 5G).
Taken together, these results suggest that loss of 53BP1
promotes HR in Brca1-deficient cells in a manner dependent
on ATM.
DISCUSSION
Interplay between NHEJ and HR Proteins in S Phase
DNA double-strand breaks can be repaired by one of two major
pathways: homology-based repair with the intact chromatid as
a template (HR) or direct joining across the break site (NHEJ).
Our data are consistent with the idea that these two DSB repair
pathways compete for repair of replication-associated chro-
matid breaks (Saberi et al., 2007; Shrivastav et al., 2008; Sonoda
et al., 2006). In WT cells, HR-mediated Xrcc2/Rad51-dependent
sister chromatid recombination is the predominant repair path-
way, and interchromosomal radial fusions are only rarely
produced (Figure 6A). In contrast, Brca1 deficiency prevents
normal HR, so that chromatid breaks, instead of being faithfully
repaired, are resolved into aberrant chromatid fusions between250 Cell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc.heterologous chromosomes. These fusions are dependent on
Lig4, a component of the classical NHEJ pathway (Figure 6B).
This shows that in the absence of normal Brca1-mediated HR,
a toxic NHEJ pathway mediates rejoining of chromatid breaks.
Although radial chromosomes are reduced in Brca1-deficient
cells that also lack Lig4, other types of DNA damage (notably
chromatid breaks) persist, and there is no rescue of HR.
By contrast, deletion of 53BP1 rescues Rad51-dependent HR
almost to WT levels in Brca1-deficient cells. 53BP1 promotes
formation of radial fusions in Brca1 mutant cells by a different
mechanism than Lig4. According to our model, 53BP1-binding
to chromatid breaks in Brca1-deficient cells interferes with HR,
not by promoting end joining per se, but rather by partially block-
ing ATM-dependent resection at the break site, which is neces-
sary for HR-mediated repair (Figures 6B and 6C). Thus, the
previously puzzling observation that loss of 53BP1 suppresses
both Brca1D11/D11lethality and tumorigenesis (Cao et al., 2009)
can now be explained by our finding that 53BP1 deficiency
rescues HR by a mechanism dependent on ATM-mediated
resection.
Our results show that DSB repair proteins have very different
abilities to affect the choice of HR versus NHEJ. 53BP1 plays
a major role in pathway choice in Brca1-deficient cells, whereas
Lig4 does not affect the initial choice of HR versus NHEJ. Defects
in HR in mammalian cells therefore might not be rescued simply
by inhibiting the activity of any protein associated with NHEJ.
Consistent with this, treatment of Brca1D11/D11 cells with an
inhibitor of the NHEJ factor DNA-dependent protein kinase
(DNA-PKcs) does not decrease the frequency of radial chromo-
some formation (Figure 4D).
Loss of 53BP1 does not have the general effect of rescuing
any defect in HR; for example, it does not normalize the genomic
instability in Xrcc2-deficient cells (Figure 3D). According to our
model, 53BP1 affects the initial stage of HR; that is, exonu-
clease-mediated resection of the DSB. Xrcc2 might be active
at a downstream stage of HR, as a cofactor of Rad51 during
strand exchange (Figures 6A and 6C). In this case, deficiency
in Xrcc2 would not be rescued by increased resection. Consis-
tent with this idea, Xrcc2 has been shown to act late during
gene conversion (Nagaraju et al., 2009).
53BP1 and Brca1 Regulate the Choice between NHEJ
and HR
The precise role of 53BP1 in NHEJ is a matter of ongoing inves-
tigation. Previous work has shown that 53BP1 is required for
long-range intrachromosomal end joining during V(D)J recombi-
nation and class-switch recombination (Difilippantonio et al.,
2008; Manis et al., 2004; Reina-San-Martin et al., 2007) as well
as fusions between dysfunctional telomeres (Dimitrova et al.,
2008). Other NHEJ-mediated events, such as the repair of
DNA damage induced by ionizing radiation, are less profoundly
affected by the absence of 53BP1 (Ward et al., 2004). This has
led to the hypothesis that 53BP1 acts as a ‘‘synapsis factor’’
required specifically for ‘‘long-range’’ joining of distant DNA
breaks by NHEJ (Difilippantonio et al., 2008; Reina-San-Martin
et al., 2007). We found that radial chromosomes are present in
Xrcc2/53BP1/ cells (Figure 3D) as well as in Brca1D11/D11
53BP1/ cells treated with ATMi (Figure 5E), demonstrating
WT Brca1Δ11/Δ11 Brca1Δ11/Δ11 53BP1-/-
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Figure 6. Model for Reversal of Genomic
Instability in Brca1D11/ D11 Cells by 53BP1
Deletion
Chromatid breaks accumulate in S phase cells as
a consequence of errors in DNA replication or
through failure of single-strand break repair (e.g.,
after PARP inhibition).
(A) InWT cells, Brca1 displaces 53BP1 fromDSBs,
enabling resection at the break site by factors
such as CtIP, which promotes RPA loading onto
single-stranded regions of DNA. RPA is displaced
by Rad51, which enables strand invasion at
the homologous region of the sister chromatid.
Rad51 acts in complex with several effectors
of HR, including Xrcc2, leading to error-free,
template-directed repair of the double-strand
breaks.
(B) In Brca1D11/ D11 cells, 53BP1 is not displaced
and inhibits resection. In the absence of resection,
the break persists, and if more than one chromatid
break is present, these breaks can be joined by
a Lig4-dependent NHEJ pathway. Joining of the
chromatid breaks produces radial chromosome
structures.
(C) In Brca1D11/ D1153BP1/ cells, 53BP1 is not
present at the double-strand break site, enabling
resection even in Brca1-deficient cells. RPA and
downstream effectors of homologous recombina-
tion are able to load normally at the break site,
permitting error-free DNA repair.
See also Figure S4.that 53BP1 is not absolutely required for long-range interchro-
mosomal joining of DNA DSBs. Consistent with this notion,
53BP1 is dispensable for AID-dependent (Ramiro et al., 2006)
and I-SceI-induced (Figure S3) translocations between c-myc
and IgH. However, by inhibiting DSB resection, 53BP1 may
increase the probability that blunt DNA ends can be ligated by
Lig4-mediated classical NHEJ. According to this hypothesis,
a key mechanism by which 53BP1 regulates the choice of HR
versus NHEJ and promotes long-range end joining could be
via inhibition of DSB resection.
Brca1 has been implicated in several processes, including
DSB repair, chromatin remodeling, cell-cycle progression, and
transcription (Yun and Hiom, 2009b). Nevertheless, very little is
known about how Brca1 contributes to these processes.
Brca1 possesses ubiquitin-ligase activity, but this function
does not appear to be essential for maintaining genomic stability
(Reid et al., 2008). On the basis of our results, we propose that
one critical function for Brca1, and perhaps other factors that
commit cells to HR, might be to remove end-joining proteins
such as 53BP1 from replication-associated breaks (Figure 6A).
Interestingly, the retention of Ku (Postow et al., 2008) and
53BP1 (Watanabe et al., 2009) is dependent on DSB-induced
ubiquitylations of these factors. While active removal of end-
joining proteins by protein ubiquitylation may promote resection
(Lee et al., 1998; Zhang et al., 2007), conversely, end resectionitself could promote dissociation of end-joining proteins
(Figure 6A). For example, Mre11/CtIP dependent DSB resection
(Lengsfeld et al., 2007; Sartori et al., 2007) and/or Mre11-depen-
dent nucleosome displacement (Tsukuda et al., 2005) might
facilitate the generation of nucleosome-free ssDNA regions
that would be incompatible with continued 53BP1 chromatin
binding but accessible for recruitment of HR proteins. Since
Brca1 forms a complex with the Mre11 and CtIP (Chen et al.,
2008; Sartori et al., 2007; Yu et al., 1998), Brca1 might play
a similar role in the dynamic removal of NHEJ proteins from
DSBs that would promote faithful sister chromatid repair and
avoid inappropriate end-ligation.
Implications for Cancer Therapy
Germline mutations in Brca1 confer susceptibility of developing
breast and ovarian cancer with high penetrance (Antoniou
et al., 2003). Cancers that develop in heterozygous carriers typi-
cally lose the second functional Brca1 allele during tumor
progression. It is possible that loss of one allele confers a defect
in HR (Cousineau and Belmaaza, 2007), and reduction in gene
dosage (haploinsufficiency) fuels sufficient genomic instability
to accelerate cancer promoting mutations, including loss of the
remaining Brca1 WT allele. Heterozygous Brca1 mutant mice
do not develop mammary tumors; however, mammary tumors
develop with a long latency in mutant mice in which Brca1 isCell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc. 251
deleted in mammary epithelium. Notably, loss of 53BP1 signifi-
cantly reduces mammary tumorigenesis in Brca1-deficient
mice (Figure 1A). Our study suggests that one therapeutic
strategy to treat Brca1 mutation carriers might be the systemic
use of compounds that inhibit 53BP1, which we predict would
render Brca1 heterozygous carriers more HR competent. One
potential side effect of this approach could be defects in B cell
immunoglobulin isotype switching, which is strictly dependent
on 53BP1 (Figure S4).
Since Brca1 is an essential gene, it remains unclear why defi-
ciency in Brca1 is tolerated in tumor cells. One possibility is that
Brca1 loss is specifically tolerated in breast and ovary. A more
likely scenario is that secondary genetic alterations arise, in addi-
tion to loss of heterozygosity at Brca1, which promote the
survival of Brca1 mutant cells. For example, loss of p53 seems
to be an essential step in Brca1-associated tumorigenesis
(Holstege et al., 2009; Xu et al., 1999). Tumors deficient in p53
and Brca1 are severely impaired in HR, and therefore sensitive
to therapies that utilize PARPi to achieve synthetic lethality.
However, treatment with PARPi provides a strong selective pres-
sure formutations that restore DSB repair capacity. Interestingly,
many Brca1-deficient tumors overexpress Rad51 (Martin et al.,
2007), which might partially restore DSB repair in these cells.
Based on our study, loss of 53BP1 is another secondary muta-
tion which would render Brca1 mutant cells HR competent and
resistant to PARP inhibitors. Similar to 53BP1 deficiency, our
model predicts that other mutations that enhance DSB resection
would make Brca1 mutant cells resistant to PARP inhibition.
However, our finding that loss of 53BP1 rescues Brca1-deficient
HR by promoting ATM-dependent resection opens a therapeutic
window for ATM inhibitors as a second line of chemotherapy for
PARP inhibitor-resistant tumors (Figure 5E and 5F). Thus, ATM
inhibitors might be used therapeutically to resensitize Brca1-
deficient tumors that develop resistance to PARPi.
EXPERIMENTAL PROCEDURES
Mice
Mice carrying the Brca1 exon 11 allele were obtained from the NCI mouse
repository, 53BP1/ mice were a gift from Junjie Chen, and Xrcc2 and Lig4
conditional mice were gifts from Peter McKinnon.
B Cell Cultures, Retroviral Transduction, and Metaphase
Preparation
Resting B lymphocytes were isolated from mouse spleens and cultured with
LPS (25 mg/ml, Sigma) and IL-4 (5 ng/ml, Sigma) as described (Calle´n et al.,
2007). ATM inhibitor (KU55993, KuDOS Pharmaceuticals) was used at 5 mM,
DNA-PK inhibitor (NU7026, Sigma) was used at 20 mM and PARP inhibitor
(KU58948, KuDOS) was used at various concentrations depending on the
experiment. Irradiation was performed with a caesium-137 source. B cells
were infected 24 hr after culture with pMX-Cre-IRES-GFP as described
(Robbiani et al., 2008). GFP+ B cells were sorted 4.5 days after infection with
a FACSAria (Becton Dickinson). For analysis of cell proliferation, CFSE
(5 mM, Molecular Probes) labeling was at 37C for 10 min. For quantification
of apoptotic cells, the PhiPhiLux G1D2 kit was used according to manufac-
turer’s protocol (OncoImmunin). For FISH analysis, metaphases were
prepared and imaged as described (Calle´n et al., 2007).
Western Blotting and Immunofluorescence
Primary antibodies were used at the following dilutions: anti-tubulin (1:15,000,
Sigma), anti-Kap-1 pS824 (1:700, Bethyl Labs), anti-RPA pS4/S8 (1:1000252 Cell 141, 243–254, April 16, 2010 ª2010 Elsevier Inc.Bethyl Laboratories), and anti-CtIP (mAb 14-1, used at 1:50, gift from Richard
Baer, Columbia University) (McBride et al., 2006). MEFs were prepared for
immunofluorescence by growth on 18 mm 3 18 mm glass coverslips.
Lymphocytes were dropped onto slides coated with CellTak (BD). Cells
were fixed with methanol, incubated with anti-Rad51 primary antibody
(H-92, Santa Cruz; used at 1:100) and detected with anti-rabbit-Alexa546 anti-
body (Invitrogen; used at 1:200).
MTT Assay
MEFs were plated at 10,000 cells/well. After growth for 4 days, MTT substrate
(Sigma) was added for 2 hr and solubilized in isopropanol according to the
manufacturer’s protocol. Plates were read with a Wallac Victor2 1420 multila-
bel counter.
shRNA
For CTIP depletion by shRNA, we obtained a construct containing the
following hairpin sequence targeting CTIP exons 7 and 8, cloned into pMX-
pie-IRES-GFP (gift of Davide Robbiani, Rockefeller University): TGCTGTTGA
CAGTGAGCGAGCTCTCTATGTACAAATGAATTAGTGAAGCCACAGATGTAA
TTCATTTGTACATAGAGAGCGTGCCTACTGCCTCGGA. Passage-immortal-
ized mouse embryonic fibroblasts were infected with this construct or empty
pMX-GFP vector. Infected cells were selected by growth inmedium containing
2 mg/ml puromycin for 1 week. Cells containing the shRNA construct were
maintained in 1 mg/ml puromycin.
GFP HR Assay
HPRT-DRGFPhyg (Nakanishi et al., 2005) was electroporated into variousMEF
cell lines, and integrants were selected in 90–125 mg/ml Hygromycin (Roche).
For each integrant, an intact copy of the DR-GFPhyg reporter was confirmed
by Southern blot with the iGFP fragment as the probe. Formeasurement of HR,
43 105 cells were plated in a 12-well tissue culture dish 24 hr prior to transfec-
tion. Cells were transfected with either an I-SceI expression vector (pCBASce)
to measure HR or a GFP expression vector (pCAGGS-NZEGFP) to measure
transfection efficiency (Pierce et al., 1999). HR relative to total transfected cells
was determined by division of the %GFP+ cells from each I-SceI transfection
by the %GFP+ cells from a parallel GFP transfection. Values represent the
mean of at least six independent transfections for each genotype, and error
bars represent the standard deviation from the mean. Statistical analysis
was performed using an unpaired t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
four figures and can be found with this article online at doi:10.1016/j.cell.
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